Aperio Group LLC boosted its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 2.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 297,267 shares of the biotechnology company’s stock after acquiring an additional 5,948 shares during the quarter. Aperio Group LLC’s holdings in Grifols, were worth $6,507,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Comerica Bank boosted its position in Grifols, by 1.3% during the 2nd quarter. Comerica Bank now owns 19,062 shares of the biotechnology company’s stock worth $389,000 after acquiring an additional 245 shares during the period. Advisor Group Inc. boosted its position in Grifols, by 2.8% during the 2nd quarter. Advisor Group Inc. now owns 11,471 shares of the biotechnology company’s stock worth $242,000 after acquiring an additional 309 shares during the period. Neuberger Berman Group LLC boosted its position in Grifols, by 0.7% during the 2nd quarter. Neuberger Berman Group LLC now owns 47,530 shares of the biotechnology company’s stock worth $1,004,000 after acquiring an additional 327 shares during the period. Bank of Montreal Can raised its stake in shares of Grifols, by 0.7% during the 2nd quarter. Bank of Montreal Can now owns 70,092 shares of the biotechnology company’s stock worth $1,480,000 after purchasing an additional 457 shares in the last quarter. Finally, Wetherby Asset Management Inc. raised its stake in shares of Grifols, by 3.0% during the 2nd quarter. Wetherby Asset Management Inc. now owns 18,731 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 544 shares in the last quarter. Hedge funds and other institutional investors own 21.84% of the company’s stock.
GRFS has been the subject of a number of recent research reports. Citigroup Inc. initiated coverage on Grifols, in a research note on Tuesday, October 31st. They set a “buy” rating for the company. Zacks Investment Research downgraded Grifols, from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, BidaskClub downgraded Grifols, from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $24.00.
Shares of Grifols, S.A. (GRFS) opened at $23.89 on Monday. The company has a debt-to-equity ratio of 1.69, a current ratio of 3.17 and a quick ratio of 1.39. The company has a market capitalization of $16,312.64, a price-to-earnings ratio of 22.33, a PEG ratio of 1.75 and a beta of 1.07.
WARNING: “Aperio Group LLC Increases Holdings in Grifols, S.A. (GRFS)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.com-unik.info/2017/11/06/aperio-group-llc-increases-holdings-in-grifols-s-a-grfs.html.
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFS).
What are top analysts saying about Grifols S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Grifols S.A. and related companies.